LordsMed, the healthcare arm of Lord’s Mark Industries Ltd, has introduced a game-changing series of bio-chemistry reagents poised to revolutionize diagnostic accuracy and preventive healthcare. These innovative reagents, encompassing 10 essential biomarkers including Triglycerides, Uric Acid, and Glucose, boast an unprecedented accuracy rate of 99.7 percent. With a shelf-life of 24 months and unique packaging, they promise prolonged usability and reliability, setting a new standard in sensitivity.
Key to this launch is LordsMed’s strategic filing of India patents, ensuring global recognition and facilitating access to international markets. Leveraging its extensive Pan-India distribution network, comprising over 300 dealers, the company aims to make these reagents widely accessible across the nation.
Moreover, LordsMed has ambitious plans to export its cutting-edge reagents to SAARC, African, and Eastern European countries, tapping into burgeoning global demand for high-quality diagnostic solutions. Sachidanand Upadhyay, MD of Lord’s Mark Industries Ltd, emphasized the transformative impact of these advancements, stating, “Our reagents will redefine diagnostic standards, enhancing early detection and preventive healthcare measures for critical diseases.”
